Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab for Prophylaxis of CRS and ICANS in Lymphoma and Multiple Myeloma
NCT07567014Phase 2Not yet recruiting
- Sponsor
- NYU Langone Health
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of emapalumab in cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), sponsored by NYU Langone Health. Planned start May 2026; status: not yet recruiting.
02
Drugs
emapalumab
03
Conditions
cytokine release syndrome (CRS)immune effector cell-associated neurotoxicity syndrome (ICANS)
Beyond the preview
Go deeper on NCT07567014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07567014.